Hepatitis C virus-related cryoglobulinemia and glomerulonephritis: Pathogenesis and therapeutic strategies

Annali Italiani di Medicina Interna

Volumn 20, Issue 2, 2005, Pages 71-80

  Garini, Giovanni ^a   Allegri, Landino ^a   Vaglio, Augusto ^a   Buzio, Carlo ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

Hepatitis C virus; Interferon ; Membranoproliferative glomerulonephritis; Mixed cryoglobulinemia; Ribavirin; Rituximab

Indexed keywords

ALPHA2A INTERFERON; ANTIVIRUS AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; RIBAVIRIN;

CRYOGLOBULINEMIA; DRUG COMBINATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; PATHOGENICITY; REVIEW; TREATMENT OUTCOME; VIROLOGY;

ADRENAL CORTEX HORMONES; ANTIVIRAL AGENTS; CRYOGLOBULINEMIA; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON ALFA-2A; RIBAVIRIN; TREATMENT OUTCOME;

EID: 24644475829     PISSN: 03939340     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. WHO. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6: 35-47.
2. Gumber SC, Chopra S. Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations. Ann Intern Med 1995; 123: 615-20.
3. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327: 1490-5.
4. Ferri C, Greco F, Longobardo G, et al. Association between hepatitis C virus and mixed cryoglobulinaemia. Clin Exp Rheumatol 1991; 9: 621-4.
5. Choo Q, Weiner AJ, Overby LR, Kuo G, Houghton M, Bradley DW. Hepatitis C virus: the major causative agent of viral non-A, non-B hepatitis. Br Med Bull 1990; 46: 423-41.
6. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.
7. Choo Q, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-62.
8. Ohno T, Lau JYN. The "gold standard", accuracy, and the current concepts: hepatitis C virus genotype and viremia. Hepatology 1996; 24: 1315-21.
9. Pileri P, Uematsu Y, Campagnoli S, et al. Binding of hepatitis C virus to CD81. Science 1998; 282: 938-41.
10. Drummer HE, Wilson KA, Poubourios P. Identification of the hepatitis C virus E2 glycoprotein binding site on the large extra-cellular loop of CD81. J Virol 2002; 76: 11143-7.
11. Farci P, Purcell RH. Clinical significance of hepatitis C virus genotypes and quasispecies. Semin Liver Dis 2000; 20: 103-26.
12. Simmonds P. Variability of hepatitis C virus. Hepatology 1995; 21: 570-83.
13. Vrielink H, Reesink HW, van den Burg PJ, et al. Performance of three generations of anti-hepatitis C virus enzyme-linked immunosorbent assays in donors and patients. Transfusion 1997; 37: 845-9.
14. Pawlotsky JM, Lonjon I, Hezode C, et al. What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories? Hepatology 1998; 27: 1700-2.
15. Beld M, Habibuw MR, Rebers SP, Boom R, Reesink HW. Evaluation of automated RNA-extraction technology and a qualitative HCV assay for sensitivity and detection of HCV RNA in pool-screening systems. Transfusion 2000; 40: 575-9.
16. Gretch D, Corey L, Wilson J, et al. Assessment of hepatitis C virus RNA levels by quantitative competitive RNA polymerase chain reaction: high-titer viremia correlates with advanced stage of disease. J Infect Dis 1994; 169: 1219-25.
17. Germer JJ, Rys PN, Thorvilson JN, Persing DH. Determination of hepatitis C virus genotype by direct sequence analysis of products generated with the Amplicor HCV test. J Clin Microbiol 1999; 37: 2625-30.
18. Scheuer PJ, Ashrafzadeh P, Sherlock S, Brown D, Dusheiko GM. The pathology of hepatitis C. Hepatology 1992; 15: 567-71.
19. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284: 450-6.
20. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology 1997; 26: 34-8.
21. Brouet JC, Clauvel JP, Danon F, Lein M, Seligmann M. Biologic and clinical significance of cryoglobulins: a report of 86 cases. Am J Med 1974; 57: 775-88.
22. Ferri C, Zignego AL, Pileri SA. Cryoglobulins. J Clin Pathol 2002; 55: 4-13.
23. Musset L, Diemert MC, Taibi F, et al. Characterization of cryoglobulins by immunoblotting. Clin Chem 1992; 38: 798-802.
24. Gorevic PD, Kassab HJ, Levo Y, et al. Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med 1980; 69: 287-308.
25. Meltzer M, Franklin EC, Elias K, McCluskey RT, Cooper N. Cryoglobulinemia. A clinical and laboratory study. II. Cryoglobulin with rheumatoid factor activity. Am J Med 1966; 40: 837-56.
26. Cacoub P, Renou C, Rosenthal E, et al, Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C (GERMIVIC). Extrahepatic manifestations associated with hepatitis C virus infection: a prospective multicenter study of 321 patients. Medicine (Baltimore) 2000; 79: 47-56.
27. Monti G, Galli M, Invernizzi F, et al. Cryoglobulinemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. GISC. Italian Group for the Study of Cryoglobulinaemias. QJM 1995; 88: 115-26.
28. Lamprecht P, Gause A, Gross WL. Cryoglobulinemic vasculitis. Arthritis Rheum 1999; 42: 2507-16.
29. Ferri C, Giuggioli D, Cazzato M, Sebastiani M, Mascia MT, Zignego AL. HCV-related cryoglobulinemic vasculitis: an update on its etiopathogenesis and therapeutic strategies. Clin Exp Rheumatol 2003; 21 (Suppl 31): S78-S84.
30. De Vita S, De Re V, Gasparotto D, et al. Oligoclonal non-neoplastic B cell expansion is the key feature of type II mixed cryoglobulinemia: clinical and molecular findings do not support a bone marrow pathological diagnosis of indolent B cell lymphoma. Arthritis Rheum 2000; 42: 94-102.
31. Monteverde A, Ballarè M, Pileri S. Hepatic lymphoid aggregates in chronic hepatitis C and mixed cryoglobulinemia. Springer Semin Immunopathol 1997; 19: 99-110.
32. Invernizzi F. Type II and type III mixed cryoglobulinemia, rheumatoid factors, hepatitis C. Semin Clin Immunol 1993; 6: 31-7.
33. Lunel F, Musset L, Cacoub P, et al. Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterology 1994; 106: 1291-300.
34. Zignego AL, Ferri C, Giannelli F, et al. Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas. Ann Intern Med 2002; 137: 571-80.
35. Ferri C, Pileri S, Zignego AL. Hepatitis C virus, B-cell disorders, and non-Hodgkin's lymphoma. In: Goedert JJ, ed. Infectious causes of cancer. Targets for intervention. Totowa, NJ: The Humana Press, 2000: 349-68.
36. Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328: 465-70.
37. Johnson RJ, Gretch DR, Couser WG, et al. Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy. Kidney Int 1994; 46: 1700-4.
38. D'Amico G. Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis induced by hepatitis C virus. Kidney Int 1998; 54: 650-71.
39. Tarantino A, Campise M, Banfi G, et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995; 47: 618-23.
40. Mehers CM, Seeff LB, Stehman-Breen CO, Hooofnagle JH. Hepatitis C and renal disease: an update. Am J Kidney Dis 2003; 42: 631-57.
41. Mazzaro C, Panarello G, Tesio F, et al. Hepatitis C virus risk: a hepatitis C virus related syndrome. J Intern Med 2000; 247: 535-45.
42. EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol 1999; 30: 956-61.
43. Lindsay KL. Therapy of hepatitis C: overview. Hepatology 1997; 26: 71S-77S.
44. Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778-89.
45. Carithers RL, Emerson SS. Therapy of hepatitis C. Meta-analysis of interferon alfa-2b trials. Hepatology 1997; 26: 83-8.
46. McHutchison JC, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-92.
47. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-32.
48. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-72.
49. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
50. Ferri C, Pietrogrande M, Cecchetti C, et al. Low-antigen-content diet in the treatment of mixed cryoglobulinemia patients. Am J Med 1989; 87: 519-24.
51. Dispenzieri A, Gorevic PD. Cryoglobulinemia. Hematol Oncol Clin North Am 1999; 13: 1315-49.
52. Ferri C, Marzo E, Longobardo G, et al. Interferon-alfa in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. Blood 1993; 81: 1132-6.
53. Dammacco F, Sansonno D, Han JH, et al. Natural interferon-alfa versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood 1994; 84: 3336-43.
54. Misiani R, Bellavita P, Fenili D, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994; 330: 751-6.
55. Mazzaro C, Lacchin T, Moretti M, et al. Effects of two different alpha-interferon regimens on clinical and virological findings in mixed cryoglobulinemia. Clin Exp Rheumatol 1995; 13 (Suppl 13): 181-5.
56. Adinolfi LE, Utili R, Zampino R, Ragone E, Mormone G, Ruggero G. Effects of long-term course of alpha-interferon in patients with chronic hepatitis C associated with mixed cryoglobulinemia. Eur J Gastroenterol Hepatol 1997; 9: 1067-72.
57. Casato M, Agnello V, Pucillo LP, et al. Predictors of longterm response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood 1997; 90: 3865-73.
58. Calleja JL, Albillos A, Moreno-Otero R, et al. Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinemia. Aliment Pharmacol Ther 1999; 13: 1179-86.
59. Cresta P, Musset L, Cacoub P, et al. Response to interferon á treatment and disappearance of cryoglobulinemia in patients infected by hepatitis C virus. Gut 1999; 45: 128-34.
60. Zuckerman E, Keren D, Slobodin G, et al. Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha. J Rheumatol 2000; 27: 2172-8.
61. Gordon AC, Edgar JD, Finch RG. Acute exacerbation of vasculitis during interferon-alpha therapy for hepatitis C-associated cryoglobulinemia. J Infect 1998; 36: 229-30.
62. Cid MC, Hernandez-Rodriguez J, Robert J, et al. Interferon-alpha may exacerbate cryoglobulinemic-related ischemic manifestations: an adverse effect potentially related to its anti-angiogenic activity. Arthritis Rheum 1999; 42: 1051-5.
63. Vassilopoulos D, Calabrese LH. Hepatitis C virus infection and vasculitis. Implications of antiviral and immunosuppressive therapies. Arthritis Rheum 2002; 46: 585-97.
64. Garini G, Allegri L, Carnevali L, Catellani W, Manganelli P, Buzio C. Interferon-alpha in combination with ribavirin as initial treatment for hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis. Am J Kidney Dis 2001; 38: E35.
65. Campise M, Tarantino A. Glomerulonephritis in mixed cryoglobulinemia: what treatment? Nephrol Dial Transplant 1999; 14: 281-3.
66. Moriconi L, Ferri C, Puccini R, et al. Double filtration plasmapheresis in the treatment of cryoglobulinemic glomerulonephritis. Int J Artif Organs 1989; 12 (Suppl 4): 83-6.
67. Vassilopoulos D, Camisa C, Strauss RM. Selected drug complications and treatment conflicts in the presence of coexistent diseases. Rheum Dis Clin North Am 1999; 25: 745-77.
68. Fong TL, Valinluck B, Govindarajan S, Charboneau F, Adkins RH, Redeker AG. Short-term prednisone therapy affects amino-transferase activity and hepatitis C virus RNA levels in chronic hepatitis C. Gastroenterology 1994; 107: 196-9.
69. Yamabe H, Johnson RJ, Gretch DR, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection responsive to interferon-alpha. Am J Kidney Dis 1995; 25: 67-9.
70. Rossi P, Bertani T, Baio P, et al. Hepatitis C virus-related cryoglobulinemic glomerulonephritis: long-term remission after antiviral therapy. Kidney Int 2003; 63: 2236-41.
71. Loustaud-Ratti V, Liozon E, Karaaslan H, et al. Interferon alpha and ribavirin for membranoproliferative glomerulonephritis and hepatitis C infection. Am J Med 2002; 113: 516-9.
72. Sarac E, Bastacky S, Johnson JP. Response to high dose interferon-á after failure of standard therapy in MPGN associated with hepatitis C virus infection. Am J Kidney Dis 1997; 30: 113-5.
73. Misiani R, Bellavita P, Baio P, et al. Successful treatment of HCV-associated cryoglobulinemic glomerulonephritis with a combination of interferon-á and ribavirin. Nephrol Dial Transplant 1999; 14: 1558-60.
74. Otha S, Yokoyama H, Wada T, et al. Exacerbation of glomerulonephritis in subjects with chronic hepatitis C virus infection after interferon therapy. Am J Kidney Dis 1999; 33: 1040-8.
75. Zaja F, De Vita S, Mazzaro C, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003; 101: 3827-34.
76. Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F. Treatment of mixed cryoglobulinemia resistant to interferon-alpha with an anti-CD20 monoclonal antibody. Blood 2003; 101: 3818-26.